Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
C4 Therapeutics Reports Promising Phase 1 Clinical Trial Results for Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at ASH Annual Meeting

Cemsidomide shows promising response rates in multiple myeloma and non-Hodgkin's lymphoma, with manageable safety profiles.Quiver AI SummaryC4 Therapeutics, Inc. presented promising clinical data at the...

CCCC : 3.95 (+2.73%)
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

CCCC : 3.95 (+2.73%)
Unusual Options Activity: Strategies for Success with Three Single-Letter Stocks

Hidden within Wednesday’s 1,211 unusually active options were 22 calls and puts whose stock symbols have a single letter. It might not seem like a great investment strategy, but single-letter stocks...

AA : 37.84 (+3.33%)
C : 69.19 (+1.13%)
BAC : 44.17 (+1.82%)
D : 53.66 (+1.26%)
DDD : 3.50 (-1.41%)
JPM : 237.60 (+1.99%)
ICF : 59.84 (+1.77%)
CCCC : 3.95 (+2.73%)
NEE : 71.67 (+2.72%)
O : 52.79 (+1.99%)
C4 Therapeutics Appoints Steve Hoerter to Board of Directors to Strengthen Oncology Expertise

C4 Therapeutics appoints Steve Hoerter to its Board, enhancing oncology expertise to advance targeted protein degradation innovations.Quiver AI SummaryC4 Therapeutics, Inc. has announced the appointment...

CCCC : 3.95 (+2.73%)
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

CCCC : 3.95 (+2.73%)
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

CCCC : 3.95 (+2.73%)
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting

CCCC : 3.95 (+2.73%)
C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

CCCC : 3.95 (+2.73%)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CCCC : 3.95 (+2.73%)
C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

CCCC : 3.95 (+2.73%)

Barchart Exclusives

Holiday Trading, Key Economic Data and Other Can't Miss Items This Week
The final trading week of 2024 arrives with shortened holiday hours and potentially thin trading volumes. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar